IL45337A - Therapeutical composition containing an isonicotinic acid hydrazide thioisonicotinic acid amide sulfones and/or sulfonamides for the treatment of mycobacterioses - Google Patents
Therapeutical composition containing an isonicotinic acid hydrazide thioisonicotinic acid amide sulfones and/or sulfonamides for the treatment of mycobacteriosesInfo
- Publication number
- IL45337A IL45337A IL45337A IL4533774A IL45337A IL 45337 A IL45337 A IL 45337A IL 45337 A IL45337 A IL 45337A IL 4533774 A IL4533774 A IL 4533774A IL 45337 A IL45337 A IL 45337A
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- activity
- sulfonamides
- dds
- acid amide
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 229940124530 sulfonamide Drugs 0.000 title claims abstract description 9
- 150000003456 sulfonamides Chemical class 0.000 title claims abstract description 8
- 230000001225 therapeutic effect Effects 0.000 title claims description 8
- -1 isonicotinic acid hydrazide thioisonicotinic acid amide sulfones Chemical class 0.000 title 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims abstract description 21
- 150000003457 sulfones Chemical class 0.000 claims abstract description 7
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 claims abstract description 5
- 230000002459 sustained effect Effects 0.000 claims abstract description 5
- VLYWMPOKSSWJAL-UHFFFAOYSA-N sulfamethoxypyridazine Chemical compound N1=NC(OC)=CC=C1NS(=O)(=O)C1=CC=C(N)C=C1 VLYWMPOKSSWJAL-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960004936 sulfamethoxypyridazine Drugs 0.000 claims abstract 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 8
- 229960001225 rifampicin Drugs 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 3
- 239000012752 auxiliary agent Substances 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 abstract description 28
- 201000008827 tuberculosis Diseases 0.000 abstract description 18
- 206010024229 Leprosy Diseases 0.000 abstract description 14
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 abstract description 4
- 229960002001 ethionamide Drugs 0.000 abstract description 2
- 229960003350 isoniazid Drugs 0.000 abstract description 2
- 229960000918 protionamide Drugs 0.000 abstract description 2
- 239000002050 international nonproprietary name Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 31
- 150000001875 compounds Chemical class 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 7
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000001549 tubercolostatic effect Effects 0.000 description 6
- 241000186362 Mycobacterium leprae Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000187492 Mycobacterium marinum Species 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 241000186363 Mycobacterium kansasii Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 241000186367 Mycobacterium avium Species 0.000 description 2
- 101710191547 Peptidyl-tRNA hydrolase 1 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000814 tuberculostatic agent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N 1-butanol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 244000026610 Cynodon dactylon var. affinis Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000186365 Mycobacterium fortuitum Species 0.000 description 1
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 1
- 241000187917 Mycobacterium ulcerans Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 229940121383 antituberculosis agent Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19732340515 DE2340515C3 (de) | 1973-08-10 | Oral applizierbares Präparat für die Behandlung der Mykobakteriosen Lepra und Tuberkulose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL45337A0 IL45337A0 (en) | 1974-11-29 |
| IL45337A true IL45337A (en) | 1977-04-29 |
Family
ID=5889387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL45337A IL45337A (en) | 1973-08-10 | 1974-07-23 | Therapeutical composition containing an isonicotinic acid hydrazide thioisonicotinic acid amide sulfones and/or sulfonamides for the treatment of mycobacterioses |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4005207A (fr) |
| BE (1) | BE818585A (fr) |
| CA (1) | CA1036939A (fr) |
| FR (1) | FR2245364B1 (fr) |
| GB (1) | GB1426996A (fr) |
| IL (1) | IL45337A (fr) |
| PH (1) | PH11010A (fr) |
| ZA (1) | ZA744888B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3127237A1 (de) * | 1981-07-10 | 1983-01-20 | Hoechst Ag, 6000 Frankfurt | Magenvertraegliche arzneiformen von xanthinderivaten und verfahren zu ihrer herstellung |
| RU2185170C1 (ru) * | 2001-01-29 | 2002-07-20 | Уральский научно-исследовательский институт фтизиопульмонологии | Туберкулостатическое средство |
| RU2182483C1 (ru) * | 2001-02-14 | 2002-05-20 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Комбинированное противотуберкулезное средство и способ его получения |
| AU2003290377A1 (en) * | 2003-01-03 | 2004-07-29 | Marton Milankovits | Pharmaceutical compositions comprising an antibacterial agent nd antifungal agent and a nitroimidazole for the treatment and prevention of genitourinary infections and their extragenital complications |
| RU2247559C1 (ru) * | 2003-12-29 | 2005-03-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Противотуберкулёзное средство |
| RU2247560C1 (ru) * | 2003-12-29 | 2005-03-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Комбинированный состав с противотуберкулёзным действием |
| RU2280451C1 (ru) * | 2005-02-24 | 2006-07-27 | Открытое акционерное общество "Щелковский витаминный завод" | Фармацевтический состав, обладающий противотуберкулезным действием |
| EP2234643B1 (fr) * | 2007-12-21 | 2013-01-09 | ETH Zurich | Composition pour le traitement de la tuberculose |
-
1974
- 1974-07-23 IL IL45337A patent/IL45337A/en unknown
- 1974-07-29 FR FR7426262A patent/FR2245364B1/fr not_active Expired
- 1974-07-31 ZA ZA00744888A patent/ZA744888B/xx unknown
- 1974-08-07 BE BE147375A patent/BE818585A/fr not_active IP Right Cessation
- 1974-08-07 US US05/495,421 patent/US4005207A/en not_active Expired - Lifetime
- 1974-08-09 CA CA206,869A patent/CA1036939A/fr not_active Expired
- 1974-08-09 PH PH16155A patent/PH11010A/en unknown
- 1974-08-12 GB GB3539974A patent/GB1426996A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE2340515B2 (de) | 1977-04-21 |
| GB1426996A (en) | 1976-03-03 |
| PH11010A (en) | 1977-10-25 |
| DE2340515A1 (de) | 1975-03-13 |
| CA1036939A (fr) | 1978-08-22 |
| ZA744888B (en) | 1975-07-30 |
| BE818585A (fr) | 1974-12-02 |
| US4005207A (en) | 1977-01-25 |
| IL45337A0 (en) | 1974-11-29 |
| FR2245364A1 (fr) | 1975-04-25 |
| FR2245364B1 (fr) | 1978-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5977099A (en) | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
| US5929066A (en) | Chromium/biotin treatment of Type II diabetes | |
| US20160051544A1 (en) | Formulations of oxabicycloheptanes and oxabicycloheptenes | |
| US20090246172A1 (en) | Compositions comprising epothilones and their use for the treatment of carcinoid syndrome | |
| CA2297834C (fr) | Traitement au chrome/biotine du diabete de type ii | |
| JPH0637395B2 (ja) | ジペプタイド誘導体を含有する、筋萎縮性側索硬化症を治療するための薬剤 | |
| US5104875A (en) | Combination preparations containing rifampicin and thioacetazon | |
| US4005207A (en) | Synergistic therapeutic composition for the treatment of mycobacterioses | |
| KR20200053069A (ko) | 시클로-히스프로를 유효성분으로 포함하는 비만 예방 또는 치료용 약제학적 조성물 | |
| US3534137A (en) | Method of systemic therapy for severe early destructive periodontal disease | |
| EP0437026A2 (fr) | Utilisation de tandospirone dans le traitement de dépression | |
| US20070287685A1 (en) | Medicinal composition containing FBPase inhibitor | |
| US20110152329A1 (en) | Use of Epothilone Derivatives for the Treatment of Hyperparathyroidism | |
| Jenkinson et al. | Cefotaxime in the treatment of pneumococcal pneumonia | |
| Shaffer et al. | Evaluation of prolonged antibiotic therapy in mice with chronic brucella infection due to Brucella melitensis | |
| EP0559728A1 (fr) | Aldehydes aromatiques et leurs derives et compositions pharmaceutiques utiles pour le traitement des maladies de la peau et de l'arthrite | |
| CN107007608A (zh) | I型和ii型糖尿病的治疗 | |
| DE2340515C3 (de) | Oral applizierbares Präparat für die Behandlung der Mykobakteriosen Lepra und Tuberkulose | |
| JP2835547B2 (ja) | 糖尿病治療剤 | |
| Kapfhammer et al. | Cimoxatone and moclobemide, two new MAO-lnhibitors, in the treatment of major depressive disorder | |
| JPS6036421A (ja) | 進行性老人性痴呆処置剤 | |
| EP0691814B1 (fr) | Procede et composition s'appliquant au traitement de l'osteoporose | |
| JP2876224B2 (ja) | 新規美白剤 | |
| AU2002366531B2 (en) | Compositions comprising epothilones and their use for the treatment of carcinoid syndrome | |
| AU2002302012B2 (en) | Chromim/biotin treatment of type II diabetes |